---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-185553"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2025-08-22T23:59:59+00:00"
generated_at: "2026-05-17T10:38:56.634576+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences doses first child in Phase 2 achondroplasia study of dabogratinib

## Summary
- First child dosed in BEACH301 Phase 2 study of dabogratinib (formerly TYRA-300) for achondroplasia.
- Initial results from safety sentinel cohort expected in second half of 2026.
- Dabogratinib is an FGFR3 inhibitor, Tyra's lead candidate for achondroplasia.

## SEC filing metadata
- accession: 0001193125-25-185553
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2025-08-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312525185553/0001193125-25-185553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312525185553/d15901d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-185553
- JSON: https://secwatch.observer/filing/0001193125-25-185553.json
- Plain text: https://secwatch.observer/filing/0001193125-25-185553.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.